Latest / DDReg Knowledge Capsule / Registering Biosimilar Drugs with Health Canada

Transcript

Registering Biosimilar Drugs with Health Canada · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Imagine spending like a billion dollars and a decade of research.
• 0:05
  Speaker 2: Yeah, a massive, massive investment.
• 0:07
  Speaker 1: Exactly. You spend all that to synthesize a life-saving therapy,
• 0:11
  Speaker 1: only to realize that because your drug is manufactured by
• 0:13
  Speaker 1: living cells, you can, well, you can never actually make
• 0:17
  Speaker 1: the exact same batch twice.
• 0:18
  Speaker 2: It's a huge paradox in biopharma.
• 0:20
  Speaker 1: It really is. Welcome to DD Regnologist Capsule. Today, we
• 0:24
  Speaker 1: are taking a deep dive into a really comprehensive guide
• 0:28
  Speaker 1: From D-D-Reg Pharma. Right.
• 0:29
  Speaker 2: The one detailing the biosimilar registration process in Canada.
• 0:33
  Speaker 1: That's the one. Yeah. And, you know, our goal here
• 0:36
  Speaker 1: is to break down this highly complex, heavily regulated pathway
• 0:40
  Speaker 1: that these lifesaving drugs have to take just to reach
• 0:42
  Speaker 1: the market.
• 0:43
  Speaker 2: It is not a simple journey, that's for sure.
• 0:45
  Speaker 1: No, not at all. So whether you are a biopharma
• 0:47
  Speaker 1: executive mapping out a market strategy, a researcher, or just,
• 0:51
  Speaker 1: you know, insanely curious about how cutting-edge medicines actually get approved,
• 0:55
  Speaker 1: This deep dive is going to be your shortcut to
• 0:57
  Speaker 1: understanding the entire Health Canada regulatory maze.
• 1:00
  Speaker 2: And the timing for unpacking this specific regulatory framework, it's
• 1:05
  Speaker 2: just crucial right now.
• 1:06
  Speaker 1: How so?
• 1:06
  Speaker 2: Well, if you connect this to the bigger picture, Health
• 1:09
  Speaker 2: Canada heavily revised its biosimilar guidance recently back in May 2026.
• 1:15
  Speaker 1: Oh, right. So the rules of the game just changed. Exactly.
• 1:18
  Speaker 2: The framework has matured significantly. We are no longer operating
• 1:23
  Speaker 2: on some experimental frontier when it comes to biosimilars. It's
• 1:27
  Speaker 2: a rigorous, structured pathway now.
• 1:30
  Speaker 1: Which means companies have to really know what they're doing.
• 1:32
  Speaker 2: Right. Mastering this process is the only way to ensure
• 1:36
  Speaker 2: these high-quality alternative therapies can actually reach patients safely and
• 1:41
  Speaker 2: do it without repeating redundant, decade-long clinical trials.
• 1:45
  Speaker 1: Okay, let's bypass the basics for a second. We all
• 1:47
  Speaker 1: understand that standard generic drugs are small molecule chemicals, right?
• 1:52
  Speaker 2: Yeah. Produced through very predictable chemical synthesis. Right.
• 1:55
  Speaker 1: You just snap the precise chemical instructions together in a
• 1:57
  Speaker 1: reactor and you get an identical rigid molecule every single time.
• 2:01
  Speaker 2: Like a perfect copy.
• 2:02
  Speaker 1: Exactly. But with biosimilars, we are dealing with these massive,
• 2:06
  Speaker 1: highly complex biologic medicines.
• 2:08
  Speaker 2: Yeah. Monoclonal antibodies, hormones, enzymes. Right.
• 2:11
  Speaker 1: And they are produced using living biological systems.
• 2:14
  Speaker 2: And that structural difference, I mean, it's just staggering.
• 2:17
  Speaker 1: Put that into perspective for us.
• 2:18
  Speaker 2: Sure. So A traditional generic, right. It might have a
• 2:22
  Speaker 2: molecular weight of, I don't know, a few hundred Daltons. Okay.
• 2:26
  Speaker 2: But a monoclonal antibody is over 150,000 Daltons.
• 2:31
  Speaker 1: Wow. That is a massive difference. It's huge.
• 2:34
  Speaker 2: We're talking about intricate three-dimensional folding structures. You're literally coaxing
• 2:40
  Speaker 2: living mammalian cells to manufacture this massive protein for you.
• 2:44
  Speaker 1: And that fundamentally changes the regulatory pathway, right? Because generics
• 2:48
  Speaker 1: use that NDS pathway, the abbreviated new drug submission, which
• 2:51
  Speaker 1: just relies on chemical equivalence. Exactly.
• 2:54
  Speaker 2: But biosimilars have to use the NDS pathway.
• 2:57
  Speaker 1: The new drug submission. Right.
• 2:59
  Speaker 2: Because they have to prove a high degree of similarity
• 3:01
  Speaker 2: to a Canadian reference biologic drug or a CRBD.
• 3:05
  Speaker 1: Okay, let's unpack this. If traditional chemical generics are like, say,
• 3:09
  Speaker 1: building a Lido set where you follow the exact instructions
• 3:12
  Speaker 1: and get the identical toy every time, biosimilars are more
• 3:15
  Speaker 1: like baking artisanal sourdough bread.
• 3:17
  Speaker 2: That is a great way to think about it.
• 3:19
  Speaker 1: Because you're relying on living yeast or living cell cultures
• 3:23
  Speaker 1: in this case. So natural variations are just inevitable. Exactly.
• 3:26
  Speaker 2: The ambient pressure, the feed media, the sheer biological chaos
• 3:30
  Speaker 2: of a living cell means every batch will have micro variations.
• 3:35
  Speaker 1: But wait, I have to push back on that. If
• 3:37
  Speaker 1: natural variations always occur and the drug literally cannot be
• 3:42
  Speaker 1: mathematically identical, How can regulators ever be sure the drug
• 3:46
  Speaker 1: is safe?
• 3:47
  Speaker 2: Well, that's the core of the issue, isn't it? Even
• 3:49
  Speaker 2: the originator drug, the reference biologic, varies from batch to
• 3:53
  Speaker 2: batch over its lifespan.
• 3:55
  Speaker 1: Oh, really? The original drug changes too?
• 3:56
  Speaker 2: Oh, absolutely. That inherent variability is why regulators rely on
• 4:01
  Speaker 2: what they call the totality of evidence approach.
• 4:03
  Speaker 1: Totality of evidence. What does that mean in practice?
• 4:06
  Speaker 2: It means they aren't looking for an identical copy. That's
• 4:08
  Speaker 2: biologically impossible. Instead, they want you to prove that any
• 4:12
  Speaker 2: minor structural differences do not result in clinically meaningful differences.
• 4:17
  Speaker 2: They need to see that there's no difference in safety, efficacy,
• 4:20
  Speaker 2: or quality compared to the reference drug.
• 4:23
  Speaker 1: So proving the totality of evidence, I imagine. requires just
• 4:26
  Speaker 1: massive amounts of data.
• 4:28
  Speaker 2: Oh, mountains of it. Which brings us to how you
• 4:31
  Speaker 2: actually submit all this.
• 4:32
  Speaker 1: Right, the submission vehicle, the CTD.
• 4:34
  Speaker 2: Yes, the Common Technical Document. It's the global standard format,
• 4:37
  Speaker 2: and it has five modules.
• 4:39
  Speaker 1: Let's run through those quickly. Sure.
• 4:40
  Speaker 2: So module one is administrative. Module two is your summaries.
• 4:44
  Speaker 2: Module three is quality documentation.
• 4:46
  Speaker 1: Okay.
• 4:47
  Speaker 2: And then module four is non-clinical data, and module five
• 4:50
  Speaker 2: is your clinical data.
• 4:51
  Speaker 1: And all of this is reviewed by the BRDD, right?
• 4:54
  Speaker 1: The Biologic and Radio Pharmaceutical Drugs Directorate at Health Canada.
• 4:58
  Speaker 2: Exactly. But here's the kicker. Module 3, the quality documentation.
• 5:02
  Speaker 2: That is by far the heaviest lift.
• 5:04
  Speaker 1: See, that feels completely counterintuitive to me. Really?
• 5:07
  Speaker 2: Why is that?
• 5:08
  Speaker 1: Well, usually we think of human clinical trials, which would
• 5:11
  Speaker 1: be Module 5, right? As the biggest, hardest hurdle in
• 5:14
  Speaker 1: drug development.
• 5:15
  Speaker 2: Right. The final boss.
• 5:16
  Speaker 1: Exactly. So why is Module 3, the manufacturing and quality data...
• 5:20
  Speaker 1: arguably the most critical part of a biosimilar submission rather
• 5:24
  Speaker 1: than the clinical trials.
• 5:26
  Speaker 2: What's fascinating here is that for biosimilars, your goal isn't
• 5:29
  Speaker 2: to reprove that the drug actually cures the disease.
• 5:32
  Speaker 1: Because the originator already did that.
• 5:34
  Speaker 2: Exactly. The original sponsor already spent billions proving the mechanism
• 5:38
  Speaker 2: of action works. Your goal as a biosimilar sponsor is
• 5:42
  Speaker 2: to prove analytical similarity.
• 5:45
  Speaker 1: Ah, so you just have to prove your version matches
• 5:47
  Speaker 1: theirs on a microscopic level.
• 5:49
  Speaker 2: Precisely. In biologics, the process is the product. So module
• 5:54
  Speaker 2: three requires this exhaustive data on your manufacturing process controls.
• 5:58
  Speaker 1: Like the cell line development and purification.
• 6:00
  Speaker 2: Yeah, product characterization, batch analysis, analytical testing methods. You have
• 6:05
  Speaker 2: to prove absolute control over your cellular factories.
• 6:08
  Speaker 1: So because you prove that high analytical similarity in the lab,
• 6:11
  Speaker 1: You don't need massive new clinical trials. Right.
• 6:14
  Speaker 2: The heavy lab data in Module 3 fundamentally justifies a
• 6:17
  Speaker 2: much smaller clinical data package in Module 5.
• 6:20
  Speaker 1: And that leads us to a concept that I think
• 6:22
  Speaker 1: is just the most powerful shortcut in this entire regulatory pathway.
• 6:26
  Speaker 2: Indication extrapolation.
• 6:28
  Speaker 1: Yes. Here's where it gets really interesting. Let's say we
• 6:32
  Speaker 1: use a pilot analogy. Extrapolation is kind of like getting
• 6:35
  Speaker 1: your pilot's license for a specific commercial passenger jet. Okay.
• 6:39
  Speaker 1: I follow. If you want to then fly a highly
• 6:42
  Speaker 1: similar cargo variant of that exact same plane, you don't
• 6:47
  Speaker 1: need to repeat all of flight school.
• 6:49
  Speaker 2: Right, because the underlying mechanics and systems are essentially the same.
• 6:53
  Speaker 1: Exactly. So in biopharma, indication extrapolation allows a biosimilar to
• 6:57
  Speaker 1: be approved for multiple diseases that the reference drug treats out.
• 7:01
  Speaker 2: Without the sponsor having to conduct separate clinical studies for
• 7:04
  Speaker 2: every single patient population.
• 7:06
  Speaker 1: Which saves years and millions of dollars. But how does
• 7:08
  Speaker 1: Health Canada actually evaluate that? They can't just take a
• 7:10
  Speaker 1: company's word for it.
• 7:11
  Speaker 2: Oh, no, they definitely don't. It is strictly evaluated. They
• 7:14
  Speaker 2: look incredibly closely at the mechanism of action, the clinical population,
• 7:18
  Speaker 2: the pharmacokinetic behavior.
• 7:20
  Speaker 1: So how the body absorbs and clears the drug.
• 7:24
  Speaker 2: Right, the PK behavior. And also immunogenicity. Health Canada does
• 7:28
  Speaker 2: not just grant this automatically.
• 7:30
  Speaker 1: Right, there must be strict boundaries.
• 7:32
  Speaker 2: Very strict. For instance... If a reference drug treats two
• 7:35
  Speaker 2: different diseases but uses completely different biological targets to do so,
• 7:41
  Speaker 2: extrapolation might just be denied entirely.
• 7:43
  Speaker 1: Because the mechanism isn't the same, the master key doesn't
• 7:46
  Speaker 1: fit the other lock.
• 7:47
  Speaker 2: Exactly. So what stands out to you? I mean, it's
• 7:49
  Speaker 2: a delicate balance, right, between speeding up market access for
• 7:53
  Speaker 2: these cheaper therapies and ensuring absolute patient safety.
• 7:57
  Speaker 1: It's a tightrope walk. And clearly, things can still go wrong.
• 8:01
  Speaker 1: Sponsors make mistakes.
• 8:03
  Speaker 2: Oh, frequently. The DD-REG guide highlights a few common pitfalls.
• 8:07
  Speaker 1: Like what? What derails these submissions?
• 8:09
  Speaker 2: Well, an incorrect reference product strategy is a big one,
• 8:12
  Speaker 2: or submitting insufficient analytical data in Module 3.
• 8:15
  Speaker 1: And if that happens, if the CTD documentation is incomplete,
• 8:18
  Speaker 1: what does Health Canada do?
• 8:19
  Speaker 2: They issue a notice of deficiency, an NOD.
• 8:22
  Speaker 1: Which basically stops the clause.
• 8:24
  Speaker 2: It stops everything. You have to go back and generate
• 8:26
  Speaker 2: the missing data.
• 8:28
  Speaker 1: Burning time and money. But Let's say you get it right.
• 8:31
  Speaker 1: You submit a flawless CTD. You prove analytical similarity. You
• 8:35
  Speaker 1: finally get the NOC, the notice of compliance.
• 8:38
  Speaker 2: The ultimate goal.
• 8:39
  Speaker 1: Right. So what does this all mean? Once you get
• 8:42
  Speaker 1: the NOC, aren't you just done? The drug is approved.
• 8:45
  Speaker 1: Why is immunogenicity still such a massive concern years after
• 8:49
  Speaker 1: the drug is on the market?
• 8:51
  Speaker 2: This raises an important question, and it goes back to
• 8:53
  Speaker 2: the very nature of biologics.
• 8:55
  Speaker 1: That's the fact that they're made from living cells.
• 8:57
  Speaker 2: Right. These are massive, complex proteins. And over time... the
• 9:00
  Speaker 2: human immune system might suddenly start recognizing them as foreign invaders. Oh, wow.
• 9:05
  Speaker 1: So your body just attacks the medicine.
• 9:07
  Speaker 2: Exactly. The body can form anti-drug antibodies. Sometimes these just
• 9:11
  Speaker 2: neutralize the drug, making it useless. But sometimes they trigger
• 9:15
  Speaker 2: severe side effects.
• 9:16
  Speaker 1: So you could take a drug safely for a year
• 9:18
  Speaker 1: and then suddenly have a reaction. Yes.
• 9:21
  Speaker 2: And that is why post-market pharmacovigilance is absolutely mandatory. It
• 9:25
  Speaker 2: is a non-negotiable requirement.
• 9:26
  Speaker 1: So approval is really just the end of the beginning.
• 9:29
  Speaker 2: You have to continuously monitor for adverse drug reactions and
• 9:32
  Speaker 2: track that immunogenicity to protect patients long term.
• 9:36
  Speaker 1: Man, that is intense. Let's recap this whole journey for
• 9:39
  Speaker 1: everyone listening, because it is a lot.
• 9:41
  Speaker 2: It's a massive process.
• 9:42
  Speaker 1: So first, biosimilars are living, complex medicines, not simple chemical generics.
• 9:48
  Speaker 2: Right.
• 9:48
  Speaker 1: And getting them approved in Canada via that NDS pathway
• 9:51
  Speaker 1: means you need a rock-solid comparability program.
• 9:54
  Speaker 2: You need a flawless CTD, especially that module three quality beta.
• 9:58
  Speaker 1: Exactly. you need a scientifically justified extrapolation strategy to maximize
• 10:03
  Speaker 1: your market reach and relentless post-market pharmacovigilance once you actually
• 10:08
  Speaker 1: get approved.
• 10:08
  Speaker 2: You really have to manage the biological chaos from start
• 10:11
  Speaker 2: to finish.
• 10:12
  Speaker 1: But, you know, thinking about all this complexity... We currently
• 10:15
  Speaker 1: rely on these highly complex living biological systems to manufacture
• 10:19
  Speaker 1: the drugs, right?
• 10:19
  Speaker 2: Yeah, living mammalian cells or bacteria.
• 10:22
  Speaker 1: Which is exactly why we have this massive regulatory burden,
• 10:26
  Speaker 1: just to prove they remain similar batch after batch.
• 10:29
  Speaker 2: Right, because of the inherent unpredictability of life. But imagine
• 10:33
  Speaker 2: a future, maybe just a decade from now.
• 10:35
  Speaker 1: Okay, what kind of future?
• 10:36
  Speaker 2: Well, imagine where AI and quantum biology can perfectly simulate
• 10:40
  Speaker 2: and predict these living cellular processes, down to the absolute
• 10:43
  Speaker 2: last atom.
• 10:44
  Speaker 1: Oh, wow. Like a perfect digital twin of a living cell.
• 10:47
  Speaker 2: Exactly. If we could instantly, purely mathematically, prove that a
• 10:52
  Speaker 2: biosimilar is a perfect match without ever even touching a
• 10:55
  Speaker 2: living cell in a lab.
• 10:57
  Speaker 1: That would change everything.
• 10:58
  Speaker 2: How radically would that transform the timeline and the cost
• 11:01
  Speaker 2: of getting these life-saving drugs into the hands of the
• 11:04
  Speaker 2: patients who need them?
• 11:05
  Speaker 1: That is mind-blowing. The regulatory framework wouldn't even need Module
• 11:09
  Speaker 1: 3 in the same way because the math would just
• 11:11
  Speaker 1: guarantee it.
• 11:12
  Speaker 2: It's something to really think about as the technology accelerates.
• 11:15
  Speaker 1: That is a phenomenal, provocative thought to end on. Thank
• 11:18
  Speaker 1: you to everyone listening for joining us on this deep
• 11:21
  Speaker 1: dive into the DD-REG guide. Keep exploring, stay curious, and
• 11:24
  Speaker 1: keep diving into the incredible world of medical innovation with us.
• 11:27
  Speaker 1: Catch you next time.